USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2
- PMID: 39256572
- DOI: 10.1038/s41388-024-03151-9
USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2
Abstract
Post-translational modifications of proteins play a pivotal role in both the initiation and progression of ovarian cancer. Despite the recognition of USP33 as a significant factor in various cancers, its specific function and underlying mechanisms in ovarian cancer remain elusive. Proteomics and ubiquitinomics approaches were coupled to screen novel substrate proteins directly regulated by USP33. Our findings unveil that USP33 was observed to eliminate K27- and K48-linked ubiquitin chains from CBX2 at the K277 position. Notably, acetylation of CBX2 at K199, catalyzed by lysine acetyltransferase GCN5, was found to enhance its interaction with USP33, subsequently promoting further deubiquitination and stabilization. Functionally, our experiments demonstrate that USP33 significantly enhances ovarian cancer proliferation and metastasis in a CBX2-dependent manner. Furthermore, analysis revealed a direct positive correlation between the expression levels of USP33 and CBX2 proteins in human specimens, with elevated levels being associated with reduced survival rates in ovarian cancer patients. These findings elucidate the mechanism by which USP33 augments ovarian cancer progression through the stabilization of CBX2, underscoring the USP33-CBX2 axis as a promising therapeutic target in ovarian cancer management.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression.Biochim Biophys Acta Gen Subj. 2025 Aug;1869(9):130830. doi: 10.1016/j.bbagen.2025.130830. Epub 2025 Jun 16. Biochim Biophys Acta Gen Subj. 2025. PMID: 40532745
-
Reduced USP33 expression in gastric cancer decreases inhibitory effects of Slit2-Robo1 signalling on cell migration and EMT.Cell Prolif. 2019 May;52(3):e12606. doi: 10.1111/cpr.12606. Epub 2019 Mar 21. Cell Prolif. 2019. PMID: 30896071 Free PMC article.
-
GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.Oncogene. 2024 Jun;43(25):1885-1899. doi: 10.1038/s41388-024-03040-1. Epub 2024 Apr 25. Oncogene. 2024. PMID: 38664501
-
Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?Expert Opin Ther Targets. 2019 Jul;23(7):565-578. doi: 10.1080/14728222.2019.1627329. Epub 2019 Jun 10. Expert Opin Ther Targets. 2019. PMID: 31177918 Review.
-
Atypical Ubiquitination and Parkinson's Disease.Int J Mol Sci. 2022 Mar 28;23(7):3705. doi: 10.3390/ijms23073705. Int J Mol Sci. 2022. PMID: 35409068 Free PMC article. Review.
Cited by
-
USP39 promote post-translational modifiers to stimulate the progress of cancer.Discov Oncol. 2025 May 13;16(1):749. doi: 10.1007/s12672-025-02573-5. Discov Oncol. 2025. PMID: 40358671 Free PMC article. Review.
-
USP33 Regulates DNA Damage Response and Carcinogenesis Through Deubiquitylating and Stabilising p53.Cell Prolif. 2025 May;58(5):e13793. doi: 10.1111/cpr.13793. Epub 2024 Dec 18. Cell Prolif. 2025. PMID: 39694539 Free PMC article.
-
Phosphorylation of USP33 by CDK1 stabilizes the mTORC2 component SIN1.Cell Death Dis. 2025 Jul 22;16(1):543. doi: 10.1038/s41419-025-07869-6. Cell Death Dis. 2025. PMID: 40695806 Free PMC article.
-
STLBRF: an improved random forest algorithm based on standardized-threshold for feature screening of gene expression data.Brief Funct Genomics. 2025 Jan 15;24:elae048. doi: 10.1093/bfgp/elae048. Brief Funct Genomics. 2025. PMID: 39736135 Free PMC article.
-
Synergistic inhibition of TNBC by USP33 and TAP63 through autophagy and ferroptosis activation.Cell Mol Life Sci. 2025 Aug 13;82(1):309. doi: 10.1007/s00018-025-05833-3. Cell Mol Life Sci. 2025. PMID: 40801947 Free PMC article.
References
-
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763 . - DOI - PubMed
-
- Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4:1239–57. https://doi.org/10.1038/s43018-023-00617-9 . - DOI - PubMed
-
- Karimi F, Azadbakht O, Veisi A, Sabaghan M, Owjfard M, Kharazinejad E, et al. Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis. Med Oncol. 2023;40:265. https://doi.org/10.1007/s12032-023-02128-0 . - DOI - PubMed
-
- Geffen Y, Anand S, Akiyama Y, Yaron TM, Song Y, Johnson JL, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023;186:3945–67.e3926. https://doi.org/10.1016/j.cell.2023.07.013 . - DOI - PubMed - PMC
-
- Tang S. Protein modifications and diseases. J Cell Physiol. 2024;239:e31194 https://doi.org/10.1002/jcp.31194 . - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical